7-氟-2,4-二甲基喹啉 | 708-72-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-氟-2,4-二甲基喹啉
• 英文名称: 7-fluoro-2,4-dimethyl-quinoline
• 英文别名: 7-Fluor-2,4-dimethyl-chinolin；7-Fluoro-2,4-dimethylquinoline
• CAS: 708-72-5
• 化学式: C₁₁H₁₀FN
• mdl: MFCD00272404
• 分子量: 175.206
• InChiKey: CGAZFIDGJQHSBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(3-fluoro-anilino)-pent-3-en-2-one 在 硫酸 作用下， 生成 7-氟-2,4-二甲基喹啉
  参考文献：
  名称：

  842.指甲的环脱水。第四部分 替代效应

  摘要：

  DOI：

  10.1039/jr9580004181

文献信息

• METHOD OF TREATING ELEVATED PLASMA CHOLESTEROL
  申请人：Institut de Cardiologie de Montréal

  公开号：EP4011877A2

  公开（公告）日：2022-06-15

  The present invention relates to compounds of Table 1, which are encompassed by Formula I and/or Formula II, III, IV, V, or VI, and pharmaceutically acceptable salts, solvates or compositions thereof. Compounds of Table 1 are PCSK9 interacting small molecules that modulate PCSK9 activity and significantly increase low density lipoprotein receptor expression and activity, lower total circulating cholesterol and are useful for treating and delaying the onset of diseases that are associated with elevated cholesterol.

  本发明涉及由式I和/或式II、III、IV、V或VI所包含的表1化合物及其药学上可接受的盐、溶液或组合物。表 1 的化合物是 PCSK9 相互作用的小分子，可调节 PCSK9 活性，显著增加低密度脂蛋白受体的表达和活性，降低循环中的总胆固醇，并可用于治疗和延缓与胆固醇升高相关的疾病的发生。
• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：ACHILLION PHARMACEUTICALS, INC.

  公开号：US20140328796A1

  公开（公告）日：2014-11-06

  The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R 1 -R 9 , R 16 , R 18 , R 19 , n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
• US8445430B2
  申请人：——

  公开号：US8445430B2

  公开（公告）日：2013-05-21
• US8785378B2
  申请人：——

  公开号：US8785378B2

  公开（公告）日：2014-07-22
• US9233136B2
  申请人：——

  公开号：US9233136B2

  公开（公告）日：2016-01-12